Company description

AVDX, ticker symbol for Advaxis Inc., is a biotechnology company that is focused on the development and commercialization of immunotherapy solutions for the treatment of cancer and infectious diseases. Founded in 2002 and headquartered in New Jersey, the company utilizes its proprietary Lm technology platform to target specific tumor types and engage the body's immune system to fight cancer. Advaxis' lead product candidate, ADXS-HPV, has shown promising results in clinical trials for the treatment of various forms of cancer, including cervical, head and neck, and anal cancers. The company also has a robust pipeline of other immunotherapy products in various stages of development. In addition, Advaxis has several collaborations and partnerships with major pharmaceutical companies, providing further validation of its technology platform. With a strong commitment to innovation and a focus on addressing unmet medical needs, Advaxis is positioned for continued growth and success in the biotechnology industry.